Co-Producer
|
|
| June
1, 2026 |
| Regional
intelligence on Drugs, Diagnostics,
Devices & Digital Health |
|
|
|
* may need subscription to view |
|
BIG4BIO
WEEKLY CEO Q&A:
Robin Toft, CEO, Curebound |
|
In this Q&A, Robin talks about her
career pivot into the nonprofit sector,
the collaborative research model that sets
Curebound apart, the growing role of
philanthropic capital to fill funding
gaps, and what it takes to build both a
high-performing team and a research
accelerator with staying power. More |
|
|
|
|
Join
us September 30 – October 1 for
LSPA’s largest partnering event of
the year. Connect with the life
sciences ecosystem throughout the
Commonwealth and beyond, get the
latest information through timely
panel discussions and learn about
the newest innovations shaping the
industry.
|
|
Learn More
→ |
|
|
- Aprea Therapeutics: Presents Updated Phase 1
Data on WEE1 Inhibitor APR-1051 at ASCO 2026,
Demonstrating Early Monotherapy Activity and
Manageable Tolerability in Advanced Solid
Tumors More
- AstraZeneca: IMFINZI (Durvalumab) Plus
IMJUDO (Tremelimumab-Actl) Combined With
Lenvatinib and TACE Reduced the Risk of
Disease Progression or Death by 30% in
Embolization-Eligible Unresectable Liver
Cancer in EMERALD-3 Phase III Trial More
- Avacta: Presents Updated Clinical Data
Showing Encouraging Early Efficacy Signals for
AVA6000 in Salivary Gland Cancers at ASCO 2026
More
- Bristol Myers Squibb: Opdivo (nivolumab) in
Combination With AVD Receives Expanded EU
Label With Approval in Frontline Advanced
Classical Hodgkin Lymphoma More
- Bristol Myers Squibb: U.S. Food and Drug
Administration Accepts for Priority Review
Supplemental New Drug Application for Camzyos
(mavacamten) to Treat Adolescents With
Symptomatic Obstructive Hypertrophic
Cardiomyopathy (oHCM) More
- Incyte: Pivotal frontMIND Trial Showed
Tafasitamab (Monjuvi/Minjuvi) Combination
Significantly Prolonged Progression-free
Survival, Reducing the Risk of Disease
Progression or Death by 25% in Patients With
Previously Untreated, High-risk DLBCL More
More
- ITM: Phase 3 COMPETE Data Supporting
Single-Timepoint Dosimetry for n.c.a.
¹⁷⁷Lu-edotreotide (ITM-11) in Patients With
Gastroenteropancreatic Neuroendocrine Tumors
(GEP-NETs) at SNMMI 2026 More
- Lungpacer Medical: Appoints Steven
Pfanstiel as Chief Financial Officer More
- Mineralys Therapeutics: Presents New Data
From the Phase 3 Launch-HTN Trial of
Lorundrostat in Participants With Hypertension
and Chronic Kidney Disease at European Meeting
on Hypertension and Cardiovascular Protection
(ESH 2026) More
- Temple University: Researchers Are Working
to Improve Treatment for Myelofibrosis More
- Virion Therapeutics: Progress Towards HBV
Functional Cure With Continued HBsAg Declines,
Without Rebound, Up to Two Plus Years, After a
Single VRON-0200 Dose, From Its Phase 1b Study
at EASL 2026 More
|
|
 |
|
Investment Banking Advisory to the
Life Science Industry |
|
Learn More
→ |
|
|
- Biotech IPO Market Strengthens in 2026, But
Quality Bar Remains High More
- BriaCell Therapeutics: Pricing of Offering More
- From Seed to Series C: What Investors Look
for Beyond the Science More
|
|
 |
Pace®
Life Sciences
The CDMO That Takes You Further.
Your partner for Product
Development, Manufacturing,
Analytical Testing, Regulatory
Consulting & Operational
Support. |
|
Learn More
→ |
|
|
- Big4Bio CEO Weekly Q&A: Robin Toft,
CEO, Curebound More
- Biotech Hangout: Episode 184 Podcast
- More on Bristol Myers Unveiling Data for One
of Its Next-Gen Blood Cancer Drugs More
- Subscribe to LifeSci Startup for
Updates on US Startups More
|
|
 |
| Life
Sciences Talent and Consulting
Strategist George Quinn Named
Partner, Fractional Talent at
Slone Partners |
|
Learn More
→ |
|
|
- Telling Your Science Story to
Investors More
- AI in Biotech: The New
Frontier for Leadership & Strategy More
- Amgen CFO to Follow David Reese Into
Retirement; Josh Smiley Is Out at Zai Lab More*
- 11 Companies Hiring in New Jersey Now More
- Empowering Students Through STEM: A
Conversation With Massachusetts Science &
Engineering Fair Executive Director Helen
Rosenfeld More
- Hiring Outlook: Job Opportunities on
BioSpace Rise YOY, but Layoffs Affect
Thousands More
- M&A in Life Sciences: The Turning Tide –
Why Now is a Strategic Inflection for
Biopharma and Biotech More
- More Than Executive Search: Building
Leadership for Every Stage of Growth More
- SJU: Path to Commercialization in Healthcare
- St Luke's University Health Network's Kira
Bub (Marketing & Public Relations) is
Interviewed by Giovanna Torchia & Jon Evoy
Podcast
|
|
|
DISCOVER COMPANIES |
|
Big4Bio: Philadelphia Life Science
Company Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
 |
|
|
|
 |
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:Philadelphia,
all rights reserved 2026
© 2026
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|
